Enfusion Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	35.6	62.55	64.37	13.94	5.9
Cash & Cash Equivalents	35.6	62.55	64.37	13.94	5.9
Cash Growth	-43.07%	-2.83%	361.80%	136.32%	-
Receivables	28.07	25.86	18.22	12.18	8.98
Other Current Assets	6.18	8.41	7.09	2.79	1.29
Total Current Assets	69.85	96.81	89.68	28.91	16.17
Property, Plant & Equipment	32.62	22.49	13.05	8.78	6.01
Other Long-Term Assets	6.5	4.48	3.36	1.4	1.02
Total Long-Term Assets	39.12	26.98	16.41	10.19	7.03
Total Assets	108.97	123.78	106.09	39.1	23.2
Accounts Payable	2.21	1.69	2.53	0.48	0.44
Current Debt	4.26	4.03	0	2.5	0.3
Other Current Liabilities	13.84	11.67	5.58	7.67	7.33
Total Current Liabilities	20.31	17.38	8.11	10.65	8.07
Long-Term Debt	11.18	2.96	0	96.06	27.36
Other Long-Term Liabilities	0	0	0.54	0.43	0.58
Total Long-Term Liabilities	11.18	2.96	0.54	96.49	27.93
Total Liabilities	31.49	20.34	8.64	107.14	36
Total Debt	15.44	6.99	0	98.56	27.66
Debt Growth	120.88%	-	-	256.38%	-
Retained Earnings	-172.93	-178.86	-171.21	0	-
Comprehensive Income	-0.41	-0.5	-0.33	-0.21	-0.1
Shareholders' Equity	53.67	65.01	55.3	-233.56	-117.88
Net Cash / Debt	20.17	55.56	64.37	-84.63	-21.76
Net Cash / Debt Growth	-63.70%	-13.69%	-	-	-
Net Cash Per Share	0.16	0.65	0.78	-	-
Working Capital	49.54	79.43	81.57	18.26	8.1
Book Value Per Share	0.61	0.76	0.67	-2.07	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).